Kala Pharmaceuticals, Inc. (KALA): Price and Financial Metrics
GET POWR RATINGS... FREE!
KALA POWR Grades
- KALA scores best on the Growth dimension, with a Growth rank ahead of 37.36% of US stocks.
- KALA's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
- KALA ranks lowest in Stability; there it ranks in the 3rd percentile.
KALA Stock Summary
- KALA's price/sales ratio is 28.03; that's higher than the P/S ratio of 92.26% of US stocks.
- Revenue growth over the past 12 months for Kala Pharmaceuticals Inc comes in at 48.59%, a number that bests 88.52% of the US stocks we're tracking.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for KALA comes in at -27% -- higher than that of just 10.37% of stocks in our set.
- Stocks that are quantitatively similar to KALA, based on their financial statements, market capitalization, and price volatility, are QUOT, VIVE, BIOL, ABEO, and NCSM.
- Visit KALA's SEC page to see the company's official filings. To visit the company's web site, go to www.kalarx.com.
KALA Valuation Summary
- KALA's price/sales ratio is 27.3; this is 658.33% higher than that of the median Healthcare stock.
- KALA's price/sales ratio has moved NA NA over the prior 49 months.
- KALA's price/sales ratio has moved NA NA over the prior 49 months.
Below are key valuation metrics over time for KALA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| KALA | 2021-01-19 | 79.2 | 4.0 | -4.4 | -5.5 |
| KALA | 2020-11-16 | 78.5 | 3.9 | -4.4 | -5.4 |
| KALA | 2020-07-22 | 99.1 | 4.0 | -6.3 | -5.6 |
| KALA | 2019-12-10 | 28.5 | 3.2 | -1.4 | -1.1 |
| KALA | 2019-08-22 | 40.0 | 2.3 | -1.5 | -1.0 |
| KALA | 2018-10-30 | NA | 2.7 | -3.9 | -2.4 |
KALA Price Target
For more insight on analysts targets of KALA, see our KALA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $20.33 | Average Broker Recommendation | 1.36 (Strong Buy) |
KALA Stock Price Chart Interactive Chart >
KALA Price/Volume Stats
| Current price | $3.56 | 52-week high | $9.97 |
| Prev. close | $3.71 | 52-week low | $3.40 |
| Day low | $3.54 | Volume | 506,885 |
| Day high | $3.71 | Avg. volume | 2,267,086 |
| 50-day MA | $5.11 | Dividend yield | N/A |
| 200-day MA | $6.87 | Market Cap | 230.13M |
Kala Pharmaceuticals, Inc. (KALA) Company Bio
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles technology. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is based in Waltham, Massachusetts.
Latest KALA News From Around the Web
Below are the latest news stories about Kala Pharmaceuticals Inc that investors may wish to consider to help them evaluate KALA as an investment opportunity.
Does Kala Pharmaceuticals (NASDAQ:KALA) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility... |
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)WATERTOWN, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 92,000 shares of Kala Pharmaceuticals common stock to sixteen new employees. The stock options were granted on July 15, 2021. The g |
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) WireKala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire |
Kala Pharmaceuticals Announces EYSUVIS Now Covered by OptumRxKala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that OptumRx, one of the largest pharmacy benefit managers (PBM) in the United States, has added EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies, |
Kala Pharmaceuticals Announces EYSUVIS® Now Covered by OptumRxKala Pharmaceuticals, Inc., today announced that OptumRx, one of the largest pharmacy benefit managers (PBM) in the United States, has added EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies, effective May 21, 2021. |
KALA Price Returns
| 1-mo | -34.68% |
| 3-mo | -53.95% |
| 6-mo | -52.09% |
| 1-year | -58.36% |
| 3-year | -70.92% |
| 5-year | N/A |
| YTD | -47.49% |
| 2020 | 83.74% |
| 2019 | -24.54% |
| 2018 | -73.55% |
| 2017 | N/A |
| 2016 | N/A |
Continue Researching KALA
Want to see what other sources are saying about Kala Pharmaceuticals Inc's financials and stock price? Try the links below:Kala Pharmaceuticals Inc (KALA) Stock Price | Nasdaq
Kala Pharmaceuticals Inc (KALA) Stock Quote, History and News - Yahoo Finance
Kala Pharmaceuticals Inc (KALA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...